Kymera Therapeutics, INC Form 4 insider transactions

Director Bruce Booth exercised stock options and sold shares of Kymera Therapeutics under a pre-arranged 10b5-1 trading plan.

Kymera Therapeutics Chief Business Officer Noah Goodman executed a series of stock transactions, including acquisitions and sales, on April 9th and 10th, 2026.

Kymera Therapeutics' Chief Operating Officer, Jeremy G. Chadwick, executed pre-planned transactions involving the exercise of stock options and subsequent sale of common stock in late March and early April 2026.

Kymera Therapeutics Director Elena Ridloff executed planned sales of common stock totaling 12,000 shares in late March and early April 2026, following option exercises.

Kymera Therapeutics' Chief Operating Officer, Jeremy G. Chadwick, exercised stock options and subsequently sold common stock shares as part of a pre-arranged Rule 10b5-1 trading plan.

Kymera Therapeutics Director Pamela Esposito exercised stock options and subsequently sold all acquired shares under a pre-arranged 10b5-1 trading plan.

Kymera Therapeutics, Inc. has granted its Chief Legal Officer, Brian Adams, 4,125 restricted stock units and options to purchase 8,250 shares of common stock, effective March 2, 2026.

Kymera Therapeutics' Chief Operating Officer, Jeremy G. Chadwick, acquired new restricted stock units and stock options while selling shares to cover tax withholding obligations.

Kymera Therapeutics' Chief Business Officer, Noah Goodman, was granted 9,225 restricted stock units and options for 18,450 shares, vesting over several years.

Kymera Therapeutics' Chief Medical Officer, Jared Gollob, was granted 17,650 restricted stock units and 35,300 stock options, while also selling 10,508 shares to cover tax obligations.

Kymera Therapeutics' CFO, Bruce N. Jacobs, was granted restricted stock units and stock options, while also selling shares to cover tax withholding obligations.

Kymera Therapeutics, Inc. CEO Nello Mainolfi was granted 215,000 stock options with an exercise price of $90.10, vesting over four years.

Kymera Therapeutics CEO Nello Mainolfi exercised stock options and subsequently sold 30,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Kymera Therapeutics Director Pamela Esposito exercised stock options and simultaneously sold 5,500 shares of common stock on January 20, 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Kymera Therapeutics CEO Nello Mainolfi exercised stock options to acquire 3,118 shares of common stock, increasing his direct beneficial ownership.

Kymera Therapeutics CEO Nello Mainolfi exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Kymera Therapeutics CEO Nello Mainolfi acquired 2,595 shares of common stock through option exercise at $38.53 per share, increasing his direct ownership.

Kymera Therapeutics Director Pamela Esposito exercised stock options and subsequently sold all resulting common shares, as detailed in a Rule 10b5-1 plan.

Kymera Therapeutics Director Bruce Booth reported the sale of 231,588 shares of common stock over three days in December 2025, executed under a Rule 10b5-1 trading plan.

Baker Bros. affiliated funds significantly increased their holdings in Kymera Therapeutics, Inc. by purchasing over 2 million shares at $86.00 each in an underwritten offering.

Kymera Therapeutics Director Jeffrey W. Albers exercised 5,000 stock options and subsequently sold all 5,000 shares of common stock on December 8, 2025, under a pre-arranged trading plan.

Kymera Therapeutics CEO Nello Mainolfi exercised 100,000 stock options and subsequently sold the acquired common shares for a significant gain.

Kymera Therapeutics' Chief Medical Officer, Jared Gollob, sold 49,307 shares of common stock on December 8, 2025, following the exercise of stock options.

Kymera Therapeutics CEO Nello Mainolfi exercised stock options and subsequently sold an equivalent number of shares under a Rule 10b5-1 plan.

Kymera Therapeutics' Chief Medical Officer, Jared Gollob, exercised stock options and subsequently sold a portion of his shares under a pre-arranged trading plan.

Kymera Therapeutics' Chief Medical Officer, Jared Gollob, executed pre-planned stock option exercises and subsequent share sales.

Kymera Therapeutics Director Jeffrey W. Albers exercised stock options and subsequently sold 5,000 shares of common stock for a significant profit, as per a pre-arranged 10b5-1 trading plan.

Kymera Therapeutics CFO Bruce N. Jacobs exercised stock options and subsequently sold 79,220 shares of common stock under a pre-arranged 10b5-1 trading plan.

Kymera Therapeutics CEO Nello Mainolfi sold 30,000 shares of common stock for $49.00 per share, following an option exercise, under a pre-arranged trading plan.

Kymera Therapeutics' Chief Legal Officer, Brian Adams, received significant equity awards, including restricted stock units and stock options, effective September 3, 2025.